Engineers Gate Manager LP Mirati Therapeutics, Inc. Transaction History

Engineers Gate Manager LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$36.54 - $54.26 $978,321 - $1.45 Million	26,774 Added 503.74%	32,089 $1.19 Million
Q4 2022 Feb 14, 2023	SELL	$41.27 - $98.62 $291,036 - $695,468	-7,052 Reduced 57.02%	5,315 $240,000
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $735,836 - $1.07 Million	12,367 New	12,367 $864,000
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $1.01 Million - $2.29 Million	-25,822 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $1.58 Million - $3.14 Million	20,806 Added 414.79%	25,822 $2.12 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $255,967 - $368,972	1,939 Added 63.02%	5,016 $736,000
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $2.06 Million - $2.77 Million	-15,588 Reduced 83.51%	3,077 $544,000
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $2.06 Million - $2.57 Million	14,284 Added 326.04%	18,665 $3.02 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $967,028 - $1.35 Million	-6,085 Reduced 58.14%	4,381 $750,000
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $1.7 Million - $2.51 Million	10,466 New	10,466 $2.3 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.